+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity



Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity



Bioscience Reports 8(4): 323-334



We studied the effect of the temporal regulation of herpes simplex virus (HSV) type 1 glycoprotein D (gD-1) expression in Ia+ epidermal cells (EC) and macrophages on virus specific immunity and protection from HSV-2 challenge. gD-1 was expressed on the surface of cells infected with a vaccinia recombinant containing gD-1 under the control of an early vaccinia virus promoter (VP176). It was not expressed in cells infected with a recombinant (VP254) in which gD-1 is controlled by a late vaccinia virus promoter. BALB/c mice immunized with both recombinants seroconverted to HSV-2 as determined by neutralization. However, HSV specific delayed type hypersensitivity (DTH) responses were significantly (p less than 0.025) higher in VP176 than VP254 immunized animals. Both VP176 and VP254 immunized mice were protected from severe neurological disease due to HSV-2 challenge at 14 days post immunization, but long term protection was observed only in VP176 immunized mice.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040108279

Download citation: RISBibTeXText

PMID: 3263886

DOI: 10.1007/bf01115223


Related references

Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity. Journal of General Virology 70: 2513-2520, 1989

Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D. Reviews of Infectious Diseases 13 Suppl 11: S924-S934, 1991

Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease. Journal of Infectious Diseases 159(4): 625-634, 1989

Control of expression of the herpes simplex virus-induced deoxypyrimidine triphosphatase in cells infected with mutants of herpes simplex virus types 1 and 2 and intertypic recombinants. Journal of Virology 43(3): 935-942, 1982

Induction of protective immunity with antibody to herpes simplex virus type 1 glycoprotein H (gH) and analysis of the immune response to gH expressed in recombinant vaccinia virus. Journal of General Virology 72: 369-375, 1991

Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins. Journal of General Virology 70: 1359-1370, 1989

Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D. Journal of Infectious Diseases 155(6): 1188-1197, 1987

Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proceedings of the National Academy of Sciences of the United States of America 84(16): 5908-5912, 1987

Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells. Journal of Virology 69(8): 4711-4716, 1995

Vaccinia virus recombinant that expresses the herpes simplex virus type 1 glycoprotein d gene protects mice against lethal challenge by herpes simplex virus type 1 or herpes simplex type 2 and the establishment of a latent ganglionic infection by herpes simplex virus type 1. Lerner, R A , R M Chanock And F Brown (Ed ) Vaccines 85: Molecular And Chemical Basis Of Resistance to Parasitic, Bacterial, And Viral Diseases; Meeting, 1983 Xxi+407p Cold Spring Harbor Laboratory: Cold Spring Harbor, N Y , Usa Illus Paper 169-174, 1985

Generation of herpes simplex virus recombinants for altering expression of neurotransmitter receptors in infected cells. Society for Neuroscience Abstracts 19(1-3): 1339, 1993

Construction of live vaccines using genetically engineered poxviruses biological activity of vaccinia virus recombinants expressing the hepatitis b virus surface antigen and the herpes simplex virus glyco protein d. Proceedings of the National Academy of Sciences of the United States of America 81(1): 193-197, 1984

Mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein d cytotoxic t cell. Journal of Virology 61(3): 726-734, 1987

The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection. Journal of Immunology 138(10): 3431-3437, 1987

Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proceedings of the National Academy of Sciences of the United States of America 93(21): 11414-11420, 1996